BG Medicine Release: Independent Multicenter Trial Demonstrates Utility Of BGM Galectin-3® Test For Accurately Classifying Risk Of Unplanned Hospital Readmissions And Adverse Outcomes In Patients With Heart Failure

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WALTHAM, Mass., Nov. 19, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today the publication of results of an independent multicenter clinical research trial in Europe that enrolled 419 heart failure patients and demonstrated that elevated levels of galectin-3 in blood, as measured using the BGM Galectin-3® Test, were significantly predictive of unplanned hospital readmissions and fatal events during the 12 month follow-up period of the trial. [1]

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC